PolarityTE (PTE) Gets a Hold Rating from Oppenheimer


In a report released today, Kevin DeGeeter from Oppenheimer maintained a Hold rating on PolarityTE (PTE). The company’s shares closed last Monday at $1.04, close to its 52-week low of $0.78.

According to TipRanks.com, DeGeeter is a 5-star analyst with an average return of 20.4% and a 47.0% success rate. DeGeeter covers the Healthcare sector, focusing on stocks such as Interpace Diagnostics Group, Rocket Pharmaceuticals, and Ionis Pharmaceuticals.

Currently, the analyst consensus on PolarityTE is a Moderate Buy with an average price target of $3.00.

See today’s analyst top recommended stocks >>

Based on PolarityTE’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $2.27 million and GAAP net loss of $12.68 million. In comparison, last year the company earned revenue of $1.33 million and had a GAAP net loss of $22.79 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

PolarityTE, Inc. is a commercial-stage biotechnology and regenerative biomaterials company, which focuses on discovering, designing and developing regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences. Its products include SkinTE, OsteoTE and Real Time Assistant. The company was founded on May 8, 1998 and is headquartered in Salt Lake City, UT.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts